Buy Emcure Pharma for the Target Rs 2,260 by Motilal Oswal Financial Services Ltd
A multi-engine growth story
* Since its inception in 1981, Emcure Pharmaceuticals (Emcure) has evolved into an R&D-driven diversified pharma franchise with a meaningful global scale built over the past decade through calibrated organic and inorganic investments across markets, platforms and capabilities.
* Emcure has built a scaled, diversified international franchise with a presence in Europe, Canada, and ROW through a wide and complex portfolio, strong Indiabased manufacturing, and enhanced commercial presence. The company delivered a 21% revenue CAGR over FY24-26 to INR52b (FY26), with EU outperforming the market by ~500bp and Canada emerging as its fastest-growing and most profitable market on the back of the Marcan/Mantra platforms, and we expect this multimarket engine to sustain a 16-18% CAGR across EU, Canada and ROW over FY26-28.
* Emcure has built a diversified, chronic-focused domestic franchise anchored to women's health leadership and expanded into cardiology, CNS, Anti-diabetes, HIV, and oncology through strong brand-building, continued investments in field force/physician coverage, and asset-light, high-ROCE partnerships (Sanofi in cardiovascular, Novo Nordisk in diabetes/obesity, Roche for Nephrology/transplant portfolio). We expect the domestic business to sustain an 11% sales CAGR over FY26-28E, reaching revenue of INR49b by FY28E.
* After moderate financial performance over FY23 and FY24 due to high investments, Emcure has delivered a superior financial performance in FY25/FY26 on the back of healthy traction in international markets, partly supported by inorganic means and currency tailwinds.
* Considering a differentiated product pipeline supporting the manufacturing base and an efficient commercial channel network, we expect a CAGR of 14%/20%/28% in revenue/EBITDA/PAT over FY26-28 to INR119b/INR26b/INR14.5b.
* The diversified earnings base with a 20% average RoE over FY26-28 leads us to assign an industry-level PE multiple of 28x to Emcure and arrive at a TP of INR2,260. Initiate coverage with BUY.
International segment: Complexity, Reach, Markets - the three pillars of Emcure's scale-up
* In the past decade, Emcure has scaled up its international business with a sizeable exposure to Europe, Canada and ROW markets. Notably, it delivered a 21% revenue CAGR over FY24-26 to INR52b (FY26; 56% of sales).
* Combining the organic/inorganic route, Emcure has built its international segment through
a) Wide portfolio, including complex products
b) A strong manufacturing base in India
c) An enhanced commercial presence.
* Specifically, in EU, Emcure has outperformed the market by ~500bp in revenue growth over FY23-26.
* Emcure was the first to launch g-Amphotericin B (USD270m market size) and has other complex products in the pipeline (Ferric Carboxymaltose, Doxorubicin). This, supported by Marketing Authorizations (MAs) from Manx acquisition, would drive 16% sales CAGR in the EU to reach INR25b over FY26-28.
* Emcure has systematically built its Canadian franchise by acquiring Marcan (FY16) to establish a national platform and Mantra Pharma (FY24) to gain access to Quebec, creating a pan-Canadian commercial presence.
* It is now leveraging this front-end to drive growth through complex generics, injectables, OTC launches and market share gains, making Canada one of its fastest-growing and most profitable international markets.
* While Emcure has expanded its differentiated portfolio with 50+ products in the pipeline, it has broadened its reach, strengthened pharmacy relationships and geographic coverage, and improved its commercial execution. Accordingly, we expect a 14% sales CAGR in Canada business to reach INR19.4b over FY26-28.
* Likewise, we expect ROW sales to reach INR26b at an 18% CAGR over FY26-28.
Valuation and view: Initiate coverage with a BUY rating
* Emcure is implementing efforts to enhance differentiated offerings to both DF and international markets through its own R&D and acquired products.
* Further, it is well-placed in terms of its manufacturing base and established commercial channel to drive revenue growth and improve profitability with better efficiency across the value chain.
* This strategy would effectively help Emcure sustain a healthy RoE of 20%. Interestingly, within our healthcare coverage universe of 29 companies, only seven companies (incl. Emcure) have an RoE of ~20%.
* Considering Emcure's robust growth prospects and healthy return ratios, we value the company at 28x 12-month forward earnings, in line with the pharma universe. Under our base-case scenario, we model a 14% revenue CAGR, 230bp margin expansion, and 22% PAT CAGR over FY26-28, arriving at a TP of INR2,260, implying a potential upside of 27%.
* The bull case scenario builds in a 20% revenue CAGR with 255bp margin expansion and a 37% PAT CAGR over FY26-28, aided by a superior execution in focus markets of EU, Canada and DF. This would lead to a TP of INR2,770, based on a 30x 12-month forward earnings multiple, implying a potential upside of 55%.
* The bear case scenario assumes a 9% revenue CAGR with 175bp margin expansion due to a delay in approvals and inferior market share gains, driving a 17% earnings CAGR over FY26-28. These factors would result in a TP of INR1,691, based on the 25x 12-month forward earnings multiple, implying a potential downside of 5%.
For More Research Reports : Click Here
For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412
